Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601705 · ClinicalTrials.gov registry record · Phase 2
Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT00601705 is a Phase 2 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 61 participants.
The verdict
NCT00601705, a Phase 2 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving chemotherapy and radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well giving combination chemotherapy, surgery, and radiation therapy works in treating patients with locoregionally advanced cancer of the esophagus, gastroesophageal junction, or stomach.
Interventions
- DRUG cisplatin
- DRUG oxaliplatin
- DRUG fluorouracil
- DRUG epirubicin hydrochloride
- PROCEDURE adjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2008-01-05 |
| Est. Completion | 2015-01-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00601705
The ClinicalTrials.gov registry entry for NCT00601705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cisplatin is the first listed.
NCT00601705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00601705 about?
NCT00601705 is a clinical study titled "Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach". RATIONALE: Drugs used in chemotherapy, such as epirubicin, oxaliplatin, fluorouracil, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemothe...
What is the current status of trial NCT00601705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2008-01-05. Estimated completion is 2015-01-23.
What interventions are being tested in trial NCT00601705?
The interventions under investigation include: cisplatin (DRUG), oxaliplatin (DRUG), fluorouracil (DRUG), epirubicin hydrochloride (DRUG), adjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00601705?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.